Vident Investment Advisory LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 48.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 128,942 shares of the biopharmaceutical company’s stock after purchasing an additional 42,292 shares during the quarter. Vident Investment Advisory LLC’s holdings in Gilead Sciences were worth $7,665,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $25,000. TFO TDC LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $27,000. Zullo Investment Group Inc. raised its stake in Gilead Sciences by 1,969.6% in the 1st quarter. Zullo Investment Group Inc. now owns 476 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 453 shares during the last quarter. Landmark Wealth Management LLC purchased a new position in Gilead Sciences in the 1st quarter worth $30,000. Finally, Artemis Wealth Advisors LLC purchased a new position in Gilead Sciences in the 1st quarter worth $32,000. Hedge funds and other institutional investors own 78.58% of the company’s stock.
Gilead Sciences Price Performance
NASDAQ:GILD opened at $65.28 on Friday. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $74.12. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $81.82 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 0.67 and a beta of 0.31. The stock’s 50-day moving average price is $62.73 and its 200-day moving average price is $61.76.
Gilead Sciences Announces Dividend
Analyst Ratings Changes
GILD has been the subject of a number of research analyst reports. Piper Sandler raised their target price on Gilead Sciences from $71.00 to $74.00 in a research note on Monday, August 15th. SVB Leerink initiated coverage on Gilead Sciences in a research note on Monday, May 23rd. They issued a “market perform” rating and a $68.00 target price for the company. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Monday, August 15th. BMO Capital Markets initiated coverage on Gilead Sciences in a research note on Tuesday, June 7th. They issued a “hold” rating and a $63.00 target price for the company. Finally, StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 17th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $72.40.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.